CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
aldesleukinbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00018941
NCT00018941Phase 3Completed
CompareCT.gov

Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma

National Cancer Institute (NCI)·interventional·Posted May 5, 2003·Updated Jun 17, 2013

In Brief

A Phase 3 clinical trial evaluating aldesleukin for Kidney Cancer. Completed, across 1 site.

Detailed Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. It is not yet known which regimen of interleukin-2 is most effective for kidney cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different regimens of interleukin-2 in treating patients who have metastatic kidney cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 5, 2003
Enrollment StartApr 1, 1991
Study CompletionMay 1, 2003
TodayJul 2, 2026
Posted 23.2 years ago

Interventions

aldesleukinbiological